STOCK TITAN

Eliem Therapeutics Inc - ELYM STOCK NEWS

Welcome to our dedicated news page for Eliem Therapeutics (Ticker: ELYM), a resource for investors and traders seeking the latest updates and insights on Eliem Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eliem Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eliem Therapeutics's position in the market.

Rhea-AI Summary
Eliem Therapeutics, Inc. (ELYM) announces the acquisition of Tenet Medicines, Inc., focusing on advancing TNT119, an anti-CD19 antibody, for autoimmune diseases. The combined company expects to have $210 million in cash, including $120 million from a private placement. The acquisition aims to fund operations until 2027 and achieve key clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.54%
Tags
-
Rhea-AI Summary
Eliem Therapeutics halts development of Kv7 program and explores strategic alternatives. The company has engaged Leerink Partners as a strategic advisor. As of June 30, 2023, Eliem had approximately $102.6 million in cash, cash equivalents, and investments in marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.43%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Eliem Therapeutics Inc

Nasdaq:ELYM

ELYM Rankings

ELYM Stock Data

119.47M
4.52M
26.12%
67.24%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Redmond

About ELYM

eliem therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. headquartered in seattle with r&d primarily in cambridge, uk, eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. these conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. at its core, the eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. eliem is a publicly traded company (nasdaq: elym) read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/